205 related articles for article (PubMed ID: 38242896)
21. Long-lasting ibogaine protection against NMDA-induced convulsions in mice.
Leal MB; de Souza DO; Elisabetsky E
Neurochem Res; 2000 Aug; 25(8):1083-7. PubMed ID: 11055745
[TBL] [Abstract][Full Text] [Related]
22. Neurochemical and Neuroendocrine Effects of Ibogaine in Rats: Comparison to MK-801.
Baumann MH; Rothman RB; Ali SF
Ann N Y Acad Sci; 1998 May; 844(1):252-264. PubMed ID: 29090818
[TBL] [Abstract][Full Text] [Related]
23. Interactions between iboga agents and methamphetamine sensitization: studies of locomotion and stereotypy in rats.
Szumlinski KK; Balogun MY; Maisonneuve IM; Glick SD
Psychopharmacology (Berl); 2000 Aug; 151(2-3):234-41. PubMed ID: 10972470
[TBL] [Abstract][Full Text] [Related]
24. Enhancement of morphine antinociception by ibogaine and noribogaine in morphine-tolerant mice.
Sunder Sharma S; Bhargava HN
Pharmacology; 1998 Nov; 57(5):229-32. PubMed ID: 9742287
[TBL] [Abstract][Full Text] [Related]
25. Acute iboga alkaloid effects on extracellular serotonin (5-HT) levels in nucleus accumbens and striatum in rats.
Wei D; Maisonneuve IM; Kuehne ME; Glick SD
Brain Res; 1998 Aug; 800(2):260-8. PubMed ID: 9685673
[TBL] [Abstract][Full Text] [Related]
26. Comparison of the hallucinogenic indole alkaloids ibogaine and harmaline for potential immunomodulatory activity.
House RV; Thomas PT; Bhargava HN
Pharmacology; 1995 Jun; 51(1):56-65. PubMed ID: 7568345
[TBL] [Abstract][Full Text] [Related]
27. A case report SPECT study and theoretical rationale for the sequential administration of ibogaine and 5-MeO-DMT in the treatment of alcohol use disorder.
Barsuglia JP; Polanco M; Palmer R; Malcolm BJ; Kelmendi B; Calvey T
Prog Brain Res; 2018; 242():121-158. PubMed ID: 30471678
[TBL] [Abstract][Full Text] [Related]
28. Unique and potent effects of acute ibogaine on zebrafish: the developing utility of novel aquatic models for hallucinogenic drug research.
Cachat J; Kyzar EJ; Collins C; Gaikwad S; Green J; Roth A; El-Ounsi M; Davis A; Pham M; Landsman S; Stewart AM; Kalueff AV
Behav Brain Res; 2013 Jan; 236(1):258-269. PubMed ID: 22974549
[TBL] [Abstract][Full Text] [Related]
29. Interactions between ibogaine, a potential anti-addictive agent, and morphine: an in vivo microdialysis study.
Maisonneuve IM; Keller RW; Glick SD
Eur J Pharmacol; 1991 Jun; 199(1):35-42. PubMed ID: 1893925
[TBL] [Abstract][Full Text] [Related]
30. DARK Classics in Chemical Neuroscience: Ibogaine.
Wasko MJ; Witt-Enderby PA; Surratt CK
ACS Chem Neurosci; 2018 Oct; 9(10):2475-2483. PubMed ID: 30216039
[TBL] [Abstract][Full Text] [Related]
31. Autoregulation of glial cell line-derived neurotrophic factor expression: implications for the long-lasting actions of the anti-addiction drug, Ibogaine.
He DY; Ron D
FASEB J; 2006 Nov; 20(13):2420-2. PubMed ID: 17023388
[TBL] [Abstract][Full Text] [Related]
32. Noribogaine generalization to the ibogaine stimulus: correlation with noribogaine concentration in rat brain.
Zubaran C; Shoaib M; Stolerman IP; Pablo J; Mash DC
Neuropsychopharmacology; 1999 Jul; 21(1):119-26. PubMed ID: 10379526
[TBL] [Abstract][Full Text] [Related]
33. Pharmacological screen for activities of 12-hydroxyibogamine: a primary metabolite of the indole alkaloid ibogaine.
Staley JK; Ouyang Q; Pablo J; Hearn WL; Flynn DD; Rothman RB; Rice KC; Mash DC
Psychopharmacology (Berl); 1996 Sep; 127(1):10-8. PubMed ID: 8880938
[TBL] [Abstract][Full Text] [Related]
34. The effects of sigma, PCP, and opiate receptor ligands in rats trained with ibogaine as a discriminative stimulus.
Helsley S; Filipink RA; Bowen WD; Rabin RA; Winter JC
Pharmacol Biochem Behav; 1998 Feb; 59(2):495-503. PubMed ID: 9477000
[TBL] [Abstract][Full Text] [Related]
35. A non-hallucinogenic psychedelic analogue with therapeutic potential.
Cameron LP; Tombari RJ; Lu J; Pell AJ; Hurley ZQ; Ehinger Y; Vargas MV; McCarroll MN; Taylor JC; Myers-Turnbull D; Liu T; Yaghoobi B; Laskowski LJ; Anderson EI; Zhang G; Viswanathan J; Brown BM; Tjia M; Dunlap LE; Rabow ZT; Fiehn O; Wulff H; McCorvy JD; Lein PJ; Kokel D; Ron D; Peters J; Zuo Y; Olson DE
Nature; 2021 Jan; 589(7842):474-479. PubMed ID: 33299186
[TBL] [Abstract][Full Text] [Related]
36. Further investigations of the serotonergic properties of the ibogaine-induced discriminative stimulus.
Helsley S; Rabin RA; Winter JC
Prog Neuropsychopharmacol Biol Psychiatry; 1999 Feb; 23(2):317-26. PubMed ID: 10368872
[TBL] [Abstract][Full Text] [Related]
37. 100 years of ibogaine: neurochemical and pharmacological actions of a putative anti-addictive drug.
Popik P; Layer RT; Skolnick P
Pharmacol Rev; 1995 Jun; 47(2):235-53. PubMed ID: 7568327
[No Abstract] [Full Text] [Related]
38. IUPHAR - invited review - Ibogaine - A legacy within the current renaissance of psychedelic therapy.
Mash DC
Pharmacol Res; 2023 Apr; 190():106620. PubMed ID: 36907284
[TBL] [Abstract][Full Text] [Related]
39. Ibogaine enhances the expression of locomotor sensitization in rats chronically treated with cocaine.
Szumlinski KK; Maisonneuve IM; Glick SD
Pharmacol Biochem Behav; 1999 Jul; 63(3):457-64. PubMed ID: 10418788
[TBL] [Abstract][Full Text] [Related]
40. Ibogaine and Subjective Experience: Transformative States and Psychopharmacotherapy in the Treatment of Opioid Use Disorder.
Brown TK; Noller GE; Denenberg JO
J Psychoactive Drugs; 2019; 51(2):155-165. PubMed ID: 30967101
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
